Allogene Therapeutics names Zachary Roberts CEO in planned succession
Allogene Therapeutics, Inc. Common Stock · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · Now $2.15
-3.1% in 1d after detection
Post-detection moves
1h
-0.4%
1d
-3.1%
3d
—
7d
—
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS